PUBLISHER: The Business Research Company | PRODUCT CODE: 1945282
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945282
Hemodynamic flow alteration devices are medical instruments designed to modify the dynamics of blood flow within the circulatory system. These devices are often utilized in procedures such as vascular surgery or heart condition treatments. They can influence factors such as the speed, direction, or resistance of blood flow to enhance circulation or reduce strain on vital organs.
The primary types of hemodynamic flow alteration devices include embolic protection devices and chronic total occlusion devices. An embolic protection device is specifically designed to capture and remove embolic material that may become dislodged during procedures such as angioplasty. This prevents the material from traveling to vital organs and causing blockages. These devices are used in various applications, including cardiovascular diseases, neurological disorders, renal conditions, and respiratory disorders, and are employed by several end users, including hospitals, clinics, ambulatory care centers, home care settings, and more.
Tariffs are impacting the hemodynamic flow alteration devices market by increasing the cost of imported medical-grade metals, polymers, guidewires, catheters, and precision-manufactured components used in embolic protection and chronic total occlusion devices. Hospitals and specialty care centers in North America and Europe are most affected due to reliance on imported interventional devices, while Asia-Pacific faces pricing pressure on export-oriented manufacturing. These tariffs are increasing device procurement costs and affecting procedure economics. However, they are also encouraging localized manufacturing, regional supplier development, and investment in domestic production capabilities for advanced cardiovascular devices.
The hemodynamic flow alteration devices market research report is one of a series of new reports from The Business Research Company that provides hemodynamic flow alteration devices market statistics, including hemodynamic flow alteration devices industry global market size, regional shares, competitors with a hemodynamic flow alteration devices market share, detailed hemodynamic flow alteration devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemodynamic flow alteration devices industry. This hemodynamic flow alteration devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hemodynamic flow alteration devices market size has grown strongly in recent years. It will grow from $0.88 billion in 2025 to $0.96 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular disorders, increasing volume of vascular intervention procedures, advancements in catheter-based technologies, wider availability of specialized interventional devices, improved clinical outcomes in flow management.
The hemodynamic flow alteration devices market size is expected to see strong growth in the next few years. It will grow to $1.3 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing adoption of precision medicine in vascular care, rising demand for minimally invasive cardiac procedures, expansion of neurovascular intervention capabilities, growing investment in advanced interventional cardiology devices, increasing focus on reducing procedural complications. Major trends in the forecast period include increasing adoption of advanced embolic protection technologies, rising use of minimally invasive flow alteration devices, growing integration of precision-guided cto devices, expansion of procedure-specific device designs, enhanced focus on patient-specific hemodynamic optimization.
The rising prevalence of cardiovascular diseases is expected to drive growth in the hemodynamic flow alteration devices market in the coming years. Cardiovascular disease (CVD) is a broad category of conditions affecting the heart and blood vessels. The increase in CVD prevalence is fueled by factors such as aging populations, poor dietary habits, sedentary lifestyles, and rising rates of conditions like hypertension and diabetes. Hemodynamic flow alteration devices are increasingly needed to manage and improve blood flow in patients with heart failure, hypertension, and arterial blockages. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million individuals in the UK are currently affected by heart and circulatory diseases-4 million men and 3.6 million women. This number is projected to rise by 1 million by 2030 and by 2 million more than current figures by 2040. Therefore, the growing prevalence of cardiovascular disease is driving the hemodynamic flow alteration devices market.
Major players in the hemodynamic flow alteration devices market are emphasizing technological innovations, such as hybrid polymer-metal flow-diverting stents, to enhance the safety, efficacy, and long-term outcomes of neurovascular interventions. Hybrid polymer-metal flow-diverting stents combine the mechanical strength of metal with the flexibility and biocompatibility of polymer, allowing controlled hemodynamic flow alteration, reduced thrombogenicity, and improved vessel healing in patients with brain aneurysms. For example, in June 2023, Fluid Biomed Inc., a Canada-based medical device company, launched REDIRECT, its first-in-human clinical trial, successfully implanting ReSolv, the world's first hybrid polymer-metal neurovascular stent. The Phase 1 study demonstrated safe implantation with no adverse events at the 30-day follow-up, marking a milestone in brain aneurysm treatment by integrating advanced materials engineering with minimally invasive neurovascular therapy to improve patient outcomes.
In October 2024, Johnson & Johnson, a pharmaceutical company based in the US, acquired V-Wave Inc. for an undisclosed sum. This acquisition is intended to bolster Johnson & Johnson's position in the cardiovascular disease sector by adding V-Wave's groundbreaking Ventura interatrial shunt to its MedTech portfolio. V-Wave Inc., a US-based company, specializes in the development of hemodynamic flow alteration devices.
Major companies operating in the hemodynamic flow alteration devices market are Cardinal Health Inc., Abbott Laboratories, Medtronic plc, Siemens Healthcare GmbH, Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., ZOLL Medical Corporation, Getinge AB, Lepu Medical Technology (Beijing) Co. Ltd., Abiomed Inc., LivaNova PLC, Cordis US Corp., Silk Road Medical Inc., Berlin Heart GmbH, CorWave SA, Jarvik Heart Inc., CARMAT SA
North America was the largest region in the hemodynamic flow alteration devices market in 2025. The regions covered in the hemodynamic flow alteration devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hemodynamic flow alteration devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The hemodynamic flow alteration devices market consists of sales of flow diverters, vascular stents, blood flow regulators, and monitoring tools. Values in and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hemodynamic Flow Alteration Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hemodynamic flow alteration devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hemodynamic flow alteration devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemodynamic flow alteration devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.